Related Experiment Video
Updated: Aug 22, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Multisystem Inflammatory Syndrome in a Young Adult (MIC-A) Following SARS-CoV-2 Infection
Ausrine Bajoriunaite1, Jurgita Zaveckiene2, Akvile Usaite3
1Department of Intensive Care, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania.
Abstract:
Multisystem Inflammatory Syndrome (MIS) is a rare but increasingly recognized complication of SARS-CoV-2 infection, usually presenting 2 to 6 weeks after the onset of COVID-19 infection symptoms and affecting mainly children. However, there have been reported several cases of a similar multisystem inflammatory syndrome in adults (MIS-A). We describe the case of a previously healthy 28-year-old male who presented with a clinical profile with multiorgan involvement within four weeks after confirmed SARS-CoV-2 infection, suggestive for multisystem inflammatory syndrome (MIS-A). The clinical presentation included persistent high grade of fever, gastrointestinal and mucocutaneous lesions, lymphadenopathy, elevated cardiac and inflammatory biomarkers, cytopenia and shock. This case report illustrates the wide range of presentations, diagnosis, and treatment modalities of multisystem inflammatory syndrome. The pathophysiology and the mechanisms by which SARS-CoV-2 triggers an abnormal immune response leading to MIS remain poorly understood. Better characterization of MIS-A and early recognition of MIS is important because it is associated with high mortality if left untreated.
Insights
Multisystem Inflammatory Syndrome in adults (MIS-A) is a rare post-COVID-19 complication. Early recognition and understanding of MIS-A are crucial due to its potential for severe outcomes.
Area of Science:
- Infectious Diseases
- Immunology
- Critical Care Medicine
Background:
- Multisystem Inflammatory Syndrome (MIS) is a rare complication of SARS-CoV-2 infection, primarily affecting children but also reported in adults as MIS-A.
- It typically manifests 2-6 weeks after initial COVID-19 symptoms.
Observation:
- A case report details a previously healthy 28-year-old male with MIS-A following confirmed SARS-CoV-2 infection.
- The patient presented with multiorgan involvement, including persistent fever, gastrointestinal and mucocutaneous lesions, lymphadenopathy, elevated cardiac and inflammatory markers, cytopenia, and shock.
Findings:
- The case highlights the diverse clinical presentations of MIS-A.
- Diagnosis and treatment modalities for MIS-A can vary widely.
Implications:
- The pathophysiology of SARS-CoV-2 triggering abnormal immune responses leading to MIS remains unclear.
- Early recognition and characterization of MIS-A are vital for timely intervention and reducing high mortality rates.
Related Concept Videos
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Endocarditis II: Clinical Features of Infective Endocarditis
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Tonsillitis I: Introduction
Etiology
Three primary contributing factors have been identified.

